Journal of Virology · 2019 · 30 citations · 52 references
Life SciencesImmunologyAutoimmunityInflammationVirologyAntiretroviral TherapyAntiviral ImmunityAntiviral TherapyHuman Immunodeficiency Virus PharmacotherapyViral LatencyViral PersistenceCd4 Positive T CellsCd4 T Cell ActivationCellular ReservoirsHiv Antiretroviral TherapyHuman Immunodeficiency Virus LatencyLatency Reversal TherapyNf-kappa B-dependent TranscriptionNf-κb Signaling
The shock-and-kill approach consists of the reactivation of HIV-1 replication from latency using latency-reversing agents (LRAs), followed by the elimination of reactivated virus-producing cells. The cellular transcription factor NF-κB is considered a master mediator of HIV-1 escape from latency induced by LRAs. Nevertheless, a systemic activation of NF-κB in HIV-1-infected patients resulting from the combined administration of different LRAs could represent a potential risk, especially in the case of a prolonged treatment. We demonstrate here that conventional treatments with bryostatin-1 and hexamethylenebisacetamide (HMBA) or ionomycin synergistically reactivate HIV-1 from latency, even under conditions where NF-κB activation is repressed. Our study provides a molecular proof of concept for the use of anti-inflammatory drugs, like aspirin, capable of inhibiting NF-κB in patients under combination antiretroviral therapy during the shock-and-kill approach, to avoid potential autoimmune and inflammatory disorders that can be elicited by combinations of LRAs.
52
Scott M. Hammer, Kathleen Squires, Michael D. Hughes et al. · New England Journal of Medicine · 1997 · 2.7K citations · Full text
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Robert C. Hastings · JAMA · 1996 · 2.4K citations